0000950170-23-034518.txt : 20230725 0000950170-23-034518.hdr.sgml : 20230725 20230725183646 ACCESSION NUMBER: 0000950170-23-034518 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230721 FILED AS OF DATE: 20230725 DATE AS OF CHANGE: 20230725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciaramella Giuseppe CENTRAL INDEX KEY: 0001786322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 231109720 MAIL ADDRESS: STREET 1: C/O BEAM THERAPEUTICS INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2023-07-21 0001745999 Beam Therapeutics Inc. BEAM 0001786322 Ciaramella Giuseppe C/O BEAM THERAPEUTICS INC. 238 MAIN STREET CAMBRIDGE MA 02142 false true false false President and CSO true Common Stock 2023-07-21 4 M false 69438 7.22 A 181728 D Common Stock 2023-07-21 4 M false 21846 7.22 A 203574 D Common Stock 2023-07-21 4 S false 155324 32.06 D 48250 D Common Stock 2023-07-24 4 M false 1206 7.22 A 49456 D Common Stock 2023-07-24 4 S false 1206 32.01 D 48250 D Stock Option (Right to Buy) 7.22 2023-07-21 4 M false 69438 0 D 2029-05-17 Common Stock 69438 20208 D Stock Option (Right to Buy) 7.22 2023-07-21 4 M false 21846 0 D 2029-05-31 Common Stock 21846 1457 D Stock Option (Right to Buy) 7.22 2023-07-24 4 M false 1206 0 D 2029-05-17 Common Stock 1206 19002 D The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. By: /s/ Christine Bellon, Attorney-in-fact 2023-07-25